EGFR and non-small cell lung carcinoma: Meanwhile, it was also found that objective response rate (ORR) was not significantly different (TP53-mut 54%, wt 66%, P=0.42) and there was a non-significant trend towards shorter mPFS on EGFR with TP53 mutation (HR 1.74, CI 0.98–3.10, P=0.06) in advanced NSCLC patients who received EGFR-TKI treatment (39).